Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Coya Therapeutics, Inc. - Common Stock (NQ: COYA )

7.990 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 7.990
Bid (Size) 3.240 (1)
Ask (Size) 12.78 (2)
Prev. Close 7.990
Today's Range 7.990 - 7.990
52wk Range 3.210 - 10.69
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Coya Therapeutics to Participate in the Mizuho Neuroscience Summit
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit
From Coya Therapeutics, Inc.
Via Business Wire

Performance

YTD
+14.80%
+14.80%
1 Month
-9.82%
-9.82%
3 Month
+33.39%
+33.39%
6 Month
+66.11%
+66.11%
1 Year
+68.57%
+68.57%

More News

Read More
Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
From Coya Therapeutics, Inc.
Via Business Wire
COYA Stock Earnings: Coya Therapeutics Reported Results for Q4 2023
Via InvestorPlace
Coya Therapeutics
Via Talk Markets
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics to Participate in BTIG Fireside Discussion
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 Conference
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 Conference
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics to Present Novel Biomarker Survival Data in Large Cohort of ALS (Amyotrophic Lateral Sclerosis) Patients at Society of Neuroimmune Pharmacology Conference
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer’s Disease and Coya’s Pathway to a “Pipeline in a Product”
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory Diseases
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Secures Key Financing In Its Fight Against Myriad Diseases
Via Benzinga
Coya Therapeutics SAB Chairman Dr. Stanley Appel, M.D. Selected as Speaker at the Society of Neuroimmune Pharmacology Conference
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics to Participate in Upcoming Chardan Biotech Leadership Call Series
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson’s Disease in Addition to Amyotrophic Lateral Sclerosis
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of COYA 302 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
From Coya Therapeutics, Inc.
Via Business Wire
Mr. Wilbur L. Ross, Former United States Secretary of Commerce, Joins Board of Coya Therapeutics, Inc.
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics’ CEO Dr. Howard Berman’s Letter to Stockholders
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Announces Closing of $26.5 Million Private Placement
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Announces $26.5 Million Private Placement
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)
From Coya Therapeutics, Inc.
Via Business Wire
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts
Via MarketBeat
Topics Bonds
Exposures Debt Markets
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.